A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of SLx-4090 in Combination With Metformin in Subjects With Type 2 Diabetes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
- HbA1c after 12 weeks
- FPG after 12 weeks
- Safety and tolerability
- Plasma levels of SLx-4090
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
-
Burbank, California, United States, 91505
-
Los Angeles, California, United States, 90036
-
Los Angeles, California, United States, 90057
-
-
Florida
-
West Palm Beach, Florida, United States, 33401
-
-
Illinois
-
Addison, Illinois, United States, 60101
-
-
Maine
-
Auburn, Maine, United States, 04210
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28211
-
Hickory, North Carolina, United States, 28602
-
Winston-Salem, North Carolina, United States, 27103
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
-
-
Texas
-
San Antonio, Texas, United States, 78229
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- HbA1c 7-11%
- On a stable dose of metformin for at least 6 weeks
Exclusion Criteria:
- Type 1 Diabetes
- Antidiabetic medication other than or in addition to metformin
- FPG > 270 mg/dL
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: 2
Placebo
|
matching tablets
|
|
Experimental: 1
SLx-4090 in combination with Metformin
|
SLx-4090
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Reduction in HbA1c
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adverse Events
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SLx-4090-09-07
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.